Enanta Pharmaceuticals (ENTA) Total Current Liabilities (2012 - 2026)

Enanta Pharmaceuticals' Total Current Liabilities history runs 15 years deep, the most recent figure standing at $46.4 million for Q1 2026.

• Quarterly Total Current Liabilities rose 1.08% year-over-year to $46.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $46.4 million (up 1.08% YoY) and the FY2025 annual result came in at $48.6 million, down 15.61% from the prior year.
• Total Current Liabilities was $46.4 million for Q1 2026 at Enanta Pharmaceuticals, up from $44.7 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $68.2 million in Q2 2023 and bottomed at $23.0 million in Q4 2022.
• A 5-year average of $46.0 million and a median of $46.4 million in 2026 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities sank 39.3% — and 2023, when it soared 196.02%.
• Enanta Pharmaceuticals' Total Current Liabilities stood at $23.0 million in 2022, then soared by 171.32% to $62.4 million in 2023, then fell by 21.4% to $49.0 million in 2024, then fell by 8.81% to $44.7 million in 2025, then rose by 3.83% to $46.4 million in 2026.
• Business Quant data shows ENTA's Total Current Liabilities at $46.4 million in Q1 2026, $44.7 million in Q4 2025, and $48.6 million in Q3 2025.